Response to Notice of Intention to Move a Resolution
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) refers to its Trading Halt Announcement that was released on 18 September 2008 regarding the Notice of Intention to Move a Resolution (the “Notice”) in relation to the proposed removal of the five directors that was received by the Company from Mervyn Jacobson ApS on Thursday, 18 September 2008 and, as contemplated, now provides the following comments in relation to the Notice, as approved by the Board:

1. Mervyn Jacobson ApS has provided no explanation in the Notice or otherwise as to why it is seeking
to remove the five directors the subject of the removal resolution.

2. Mr. Ohanessian was appointed as CEO/MD with the unanimous consent of the Board, including Dr.Jacobson, on 24 September 2007. The Board remains resolute in its decision to support Mr. Ohanessian who has its full confidence and support and who it considers is dedicated, high performing and hard working.

3. A decision relating to the position of CEO/MD is properly one for a board rather than shareholders.The Board seeks to carry out its duties in the best interests of all shareholders, large and small, and considers that if the resolution is passed it would not be in the interests of shareholders. If shareholders impugn the judgment of the Board by voting to override it, the four independent directors the subject of the Notice removal aside from Mr. Ohanessian have advised that they will be unable to continue to properly carry out their duties to the Company and shareholders as a whole.

The trading halt in the Company’s shares can now be lifted.